Company Overview of E. Claiborne Robins Company, Inc.
E. Claiborne Robins Company, Inc., doing business as ECR Pharmaceuticals, manufactures and sells pharmaceutical products to healthcare professionals and patients. It offers products for the treatment of symptoms related to allergy, cough and cold, analgesics, and poison ivy and dermatitis; Zolpimist Oral Spray, a delivery system of prescribed sleep aid; and Lodrane D, an adult brompheniramine. The company also provides patient assistance programs. It sells its products through wholesale suppliers. E. Claiborne Robins Company, Inc. was founded in 1990 and is based in Richmond, Virginia. As of June 20, 2014, E. Claiborne Robins Company, Inc. operates as a subsidiary of Valeant Pharmaceuticals ...
3969 Deep Rock Road
Richmond, VA 23233
Founded in 1990
Key Executives for E. Claiborne Robins Company, Inc.
Chief Executive Officer and President
Compensation as of Fiscal Year 2014.
E. Claiborne Robins Company, Inc. Key Developments
ECR Pharmaceutical Co., Inc. Announces Management Changes
Mar 13 13
Davis Caskey, Vice President Pharmaceutical Operations of ECR Pharmaceutical Co., Inc., a wholly owned subsidiary of the Company, has announced that he will be retiring from the company effective March 31, 2013. On March 11, 2013, the company appointed Cameron Durrant to the positions of President and Chief Executive Officer pursuant to an employment agreement. Dr. Durrant has been a consultant for the company for the past six months and worked in the pharmaceutical industry for 22 years, and in medical practice for 8 years prior. He has been CEO or interim CEO for four venture-backed companies and CFO of a public company. He has been a senior executive at Johnson and Johnson, Pharmacia Corporation (until its acquisition by Pfizer), GSK and Merck.
E. Claiborne Robins Company, Inc. Announces Sales Results for the Second Quarter 2013
Dec 6 12
E. Claiborne Robins Company, Inc. announced sales results for the second quarter 2013. For the quarter, sales rose 59% to $5.6 million from $3.5 million in the prior year. The increase was led by Bupap, which had strong unit sales ahead of announced price increase in the month of September.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 20, 2014
Most Searched Private Companies
Sponsored Financial Commentaries